Data Source
We evaluated the Cochrane systematic review of randomised controlled trials [1] . Trials were identified by searching Medline, Embase, Central Cochrane Library, Cochrane Dementia and Cognitive Improvement Group database, abstract from proceedings of the main Dementia Conferences, and by contacting the pharmaceutical company, Novartis, for unpublished and published trials. 
Treatment
Rivastigmine 1-12 mg two to three times a day for 6 months. Two treatment groups were identified, rivastigmine 1-4 mg/day (group 1) or 6-12 mg/day (group 2).
Outcome Measures
The primary outcomes chosen were the ratings of cognitive tests [cognitive functions assessed by the Alzheimer's Disease Assessment Scale (ADAS-Cog) and the MMSE], a functional scale [Progressive Deterioration Scale (PDS)], and a global measure [Clinician's Interview-Based Impression of Change Scale (CIBIC-Plus)] in comparison with baseline scores, and, as measure of tolerability to the treatment, the number of patients that dropped out due to adverse events.
Quality of the Studies
All trials were randomised with adequate concealment, doubleblind, parallel group and all were placebo controlled. There was approximately a 17% drop-out rate in the placebo group and in the rivastigmine group 1, increasing to 35% in the rivastigmine group 2. Only a third of the patients that dropped out were retrieved and included in an 'intention to treat' analysis.
Main Results
Seven trials involving 3,370 patients with mild AD were included. At the 26 weeks' follow-up, rivastigmine 6-12 mg/day was associated with an improvement in ADAS-Cog, in activities of daily living assessed by PDS, and in the dichotomised CIBIC-Plus Scale. The main adverse events were gastrointestinal (nausea, vomiting, diarrhoea, anorexia, or abdominal pain), severe enough to cause some patients receiving rivastigmine 6-12 mg/day to drop out from the study (table 1). WMD = Weighted mean difference; OR = odds ratio; CI = confidence interval; Patients = patients treated with rivastigmine; Controls = controls treated with placebo; ARR = absolute risk reduction; NNH = number needed to harm.
